Biocryst Pharmaceuticals (BCRX) Non-Current Assets (2010 - 2026)

Biocryst Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $91.4 million for Q1 2026.

• Quarterly Non-Current Assets rose 30.48% year-over-year to $91.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $350.7 million (up 12.55% YoY) and the FY2025 annual result came in at $109.8 million, up 60.42% from the prior year.
• Non-Current Assets was $91.4 million for Q1 2026 at Biocryst Pharmaceuticals, down from $109.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $109.8 million in Q4 2025 and bottomed at $15.7 million in Q2 2022.
• A 5-year average of $51.6 million and a median of $49.6 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 58.75% — and 2024, when it jumped 478.69%.
• Biocryst Pharmaceuticals' Non-Current Assets stood at $33.5 million in 2022, then plunged by 37.33% to $21.0 million in 2023, then soared by 226.06% to $68.5 million in 2024, then surged by 60.42% to $109.8 million in 2025, then declined by 16.74% to $91.4 million in 2026.
• Business Quant data shows BCRX's Non-Current Assets at $91.4 million in Q1 2026, $109.8 million in Q4 2025, and $90.7 million in Q3 2025.